Canada Markets open in 4 hrs 6 mins

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.55-0.27 (-4.64%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.82
Open5.82
Bid5.51 x 900
Ask5.56 x 1200
Day's Range5.24 - 5.87
52 Week Range3.10 - 8.06
Volume1,284,682
Avg. Volume542,869
Market Cap203.086M
Beta (5Y Monthly)3.58
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateNov. 02, 2021 - Nov. 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.20
  • GlobeNewswire

    Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

    WARREN, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd. The Aquestive team is scheduled to a hold a fireside chat that is available on demand starti

  • Motley Fool

    Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Transcript

    On today's call, I am joined by Keith Kendall, chief executive officer; and Ernie Toth, chief financial officer, who are going to provide an overview of recent business developments and performance in the third quarter 2021, followed by a Q&A session. As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. A description of these measures along with a reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.

  • Zacks

    Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

    Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 7.50% and 10.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?